Previous 10 | Next 10 |
Ligand Pharmaceuticals ( LGND +1.1% ) has acquired the economic rights to Novan's ( NOVN -0.5% ) SB206, a topical antiviral gel in Phase 3 development for skin infections, for $12M in upfront cash, up to $20M in milestones and tiered royalties of 7 - 10%. More news on: Ligand Pharmac...
Novan to immediately receive $12 million of non-dilutive capital Ligand to receive milestones and tiered royalty for North America SB206 molluscum indication Phase 3 molluscum trial to begin recruitment of patients this month Molluscum top line results targeted early during the ...
Phase 3 drug candidate targeting molluscum Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections, including molluscum contagiosum. Ligand...
Ligand Pharmaceuticals Inc. (LGND) Q1 2019 Earnings Conference Call May 2, 2019 4:30 PM ET Company Participants Todd Pettingill – Investor Relations John Higgins – Chief Executive Officer Matt Foehr – Chief Operating Officer Matt Korenberg – Chief Fi...
Ligand Pharmaceuticals (NASDAQ: LGND ): Q1 Non-GAAP EPS of $1.16; GAAP EPS of $31.32 beats by $1.43 . More news on: Ligand Pharmaceuticals Incorporated, Earnings news and commentary, Healthcare stocks news, Read more ...
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2019 and provided an operating forecast and program updates. Ligand management will host a conference call ...
Top-line data expected Q3 of 2019 Also reports recent results from clinician survey on radiocontrast agent selection and use Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces completion of enrollment of the Company’s Phase 1 clinical trial of its internal C...
Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2019 financial results on May 2, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call. Fir...
From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-08-02 00:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...